EU SolidAct – a pan-European platform for pandemic research and preparedness

There is an urgent need for rapid and coordinated investigation of new candidate drugs during pandemics. EU-SolidAct is an Adaptive Platform Trial developed to evaluate drug interventions in hospitalized patients with COVID-19 and to facilitate a joint European response to future pandemics. The first drug to be tested is baricitinib, a tablet prescribed for treatment of rheumatoid arthritis. This drug has also shown promising results for patients with severe COVID-19.

EU-SolidAct has now started inclusion of patients in Norway and will recruit patients from around fifteen European countries. The trial is sponsored by Oslo University Hospital, Norway.

 

More content coming soon